Fangzhou Raises HK$150 Million in Share Placement to Accelerate AI-Powered Chronic Care Platform

Core Viewpoint - Fangzhou Inc. has successfully completed a HK$150 million share placement to enhance its balance sheet and accelerate investments in AI and platform upgrades [1][2]. Group 1: Fundraising and Financials - The shares were priced at HK$3.32 each, representing approximately 3.26% of the Company's enlarged issued share capital post-subscription [2]. - Fangzhou plans to allocate around 90% of the net proceeds to develop its AI-driven chronic disease management platform, focusing on model development, infrastructure expansion, talent recruitment, data collection, and marketing of AI-enhanced services [3]. - The fundraising follows a positive profit alert, with projected 2025 revenue between RMB 3.5 billion and RMB 3.55 billion, indicating a year-on-year growth of approximately 30%, and a net profit of RMB 7 million to RMB 10 million, marking the first full year of profit for the Company [6]. Group 2: Industry Context and Strategic Direction - The fundraising occurs amid a resurgence in medical AI, as both global and domestic technology players are advancing healthcare-focused large language models (LLMs) [4]. - Fangzhou has completed a significant upgrade of its "AI + H2H (Hospital-to-Home)" ecosystem, integrating AI throughout the chronic disease management value chain to enhance patient care and medical resource efficiency [4]. - The Company is positioned as a leader in AI-enabled chronic care, attracting attention from institutional investors as China's healthcare sector explores innovative models [5]. - Looking forward, Fangzhou aims to leverage technology and AI to improve chronic disease management and support China's "Healthy China 2030" initiative [7]. Group 3: Company Overview - Fangzhou Inc. is recognized as China's leading online chronic disease management platform, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [8]. - The Company specializes in providing tailored medical care and AI-enabled precision medicine solutions [8].